Compare Amphastar Pharmaceuticals Inc (AMPH) vs EPR Properties (EPR) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

EPR Properties trades at $59.62, up 0.08% on the day, with a bullish technical signal from moving averages. The REIT shows strong profitability with a 39.93% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights a $315 million Six Flags acquisition and monthly dividends, reinforcing its experiential real estate focus.

Outlook remains positive with a consensus price target of $63.00, though risks include portfolio transition execution and sensitivity to consumer discretionary spending. The stock offers a 6%+ yield with solid coverage, appealing for income investors amid stable occupancy and growth initiatives.